A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031)

Exclusion Criteria

• •Is currently participating in, or has participated in a study with an investigational agent or device within 4 weeks prior to first dose of study therapy
• •Has a diagnosis of immunosuppression or has received systemic steroid therapy, or any other form of immunosuppressive therapy within 4 weeks prior to first dose of study therapy
• •Has had prior chemotherapy, targeted small molecule, or radiation therapy for treatment of RCC
• •Has a known additional (other than RCC) malignancy that is progressing or requires active treatment
• •Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
• •Has an active, or documented history of autoimmune disease, with the exceptions of vitiligo or resolved childhood asthma/atopy
• •Has a history of (non-infectious) pneumonitis that required treatment with steroids or current pneumonitis.
• •Has an active infection requiring systematic therapy
• •Is receiving anticoagulant therapy, with the exception of low dosage aspirin
• •Has severe cardiovascular disease or symptomatic ischemic heart disease
• •Has hepatic decompensation
• •Has uncontrolled thyroid dysfunction
• •Has uncontrolled diabetes mellitus
• •Has known psychiatric or substance abuse disorders
• •Female is pregnant or breastfeeding
• •Is expecting to conceive children within the projected maximum duration of the trial, extending through 120 days after the last dose of treatment or the last blood draw
• •Has received prior therapy with any antibody or drug (including ipilimumab) specifically targeting T-cell co-stimulation or checkpoint pathway
• •Has a known history of human immunodeficiency virus (HIV)
• •Has known active hepatitis B or C
• •Has received a live vaccine within 30 days prior to screening